Our thesis
The prescription treats the disease. The protocol treats the patient. Medicine built them as rivals. They were always supposed to be complementary.
01 — The split
Healthcare built two separate tracks. One writes the prescription — fast, scalable, reimbursable, and, on its own, not enough to keep most patients on a GLP-1 (glucagon-like peptide-1), a statin, or a hormone therapy long enough to get its full benefit. The other is lifestyle medicine — nutrition, fitness, sleep, stress, and the daily habits proven to change outcomes, but historically boutique, slow to scale, and disconnected from the prescription itself.
Patients experience this as two systems that don’t talk to each other, not one plan. And when a therapy fails, it’s rarely the molecule’s fault — it’s that the patient quit before it had a chance to work, or never got the lifestyle support that would have made the difference. That’s a lifestyle-medicine problem wearing a pharma outcome.
This is decided by what happens between the prescription and the next refill — whether the domains below work as one coordinated plan built around the drug, or as disconnected point solutions the patient quietly abandons.
Prescription medicine
Fast, scalable, reimbursable.
Lifestyle medicine
The point
Patients experience this as two systems that don’t talk to each other, not one plan.
02 — The gap
Pharma manufacturers built the molecule — and, increasingly, their own direct-to-consumer pharmacies. Retail pharmacies built distribution. Health plans built utilization management. Lifestyle-medicine practitioners built their own practices, largely disconnected from whatever the patient was prescribed. Each side optimized its own half.
Nobody built the layer in between: a system that turns a specific prescription, a patient’s labs, symptoms, and history into a structured, evidence-cited protocol a licensed dietitian and trainer can act on — chosen and calibrated to the medication the patient is actually taking. That bridge between the prescription and the lifestyle medicine that makes it work is the piece nobody built. It’s also the hardest piece, which is the honest reason it stayed open: it requires reasoning grounded in versioned clinical rules, not a model’s best guess, and a workflow built for a multidisciplinary care team rather than a single sign-off. We built Tera to meet that requirement from day one — the architecture behind it lives on our Safe AI page.
Today that bridge takes two forms. Medication Companions — coaching built around a specific drug, sold to the manufacturers, pharmacies, and health plans who need their patients to stay on it. And Tera AI Clinical Copilots — the same clinical reasoning and protocol engine, licensed directly into platforms already reaching those patients. Both run on one engine, proven first inside TeraPro, the practice platform lifestyle-medicine clinicians use every day.
Medication Companions
Tera AI Clinical Copilots
03 — Why now
Capability
Language models finally got capable enough to be useful inside a constrained clinical system — fluent enough to parse messy patient data, structured enough to be governed by deterministic rules rather than left to their own judgment. That gap between capable and trustworthy is exactly why Safe AI was the unlock: a model good enough to draft but not yet good enough to decide is precisely the tool a rules-anchored system was built for.
Market
GLP-1 therapy alone crossed into a scale and a persistence problem that pharma, pharmacies, and health plans can no longer treat as background noise — a large share of patients discontinue within the first year, most of it over side effects, not the drug failing. Manufacturers are now selling direct to patients themselves. Health plans are gating coverage on proof of lifestyle participation. Retail pharmacies are looking for a reason beyond the drug to keep the patient. All three are looking for the same missing layer, at the same time.
The window
Neither curve was there three years ago. Neither will still be open in three more — outcome data compounds, and whoever has been running supervised, evidence-cited protocols the longest will have the best model of what actually keeps a patient on treatment. This gets built once, in this window.
04 — Our beliefs
The prescription and the protocol are not rivals. Treated as one coordinated plan, they outperform either running alone.
Retention is a clinical problem before it is a business problem. Solve the first, and the second follows.
The first weeks on a new prescription predict the next year of adherence.
Tera generates structured, evidence-cited findings for the care team — a licensed dietitian, a trainer, and a prescriber where one is involved — to review and act on. The care team decides, every time, no exceptions.
One coordinated plan across nutrition, supplements, fitness, sleep, stress, and eliminations — not six disconnected point solutions — because the patient is on one medication and has one life.